Mereo BioPharma Group plc

NASDAQ:MREO

Biotechnology

Healthcare
$0.32 +9.69%

+$0.03 today

Market cap
$51.08M
Beta
0.28
P/E (TTM)
-1.4
EPS (TTM)
-$0.22
52W Low $0.20High $3.05

Volume 1.26M

Average 3.36M

MREO Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Mereo BioPharma Group plcNASDAQ: MREO

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin not reported for Q1 FY2026

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
73.4%— YoY
LTMMar 2026
-105.7%— YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
73.4%
Year-over-year change
—

Gross Margin vs competitors

How MREO compares with its peers on the latest reported figures

  • MREO's LTM Mar 2026 gross margin of -105.7% is the 4th highest of the 5 companies compared; the peer median is 78.1%.
MREO Competitors Peer median
Gross Margin for MREO and competitors
Company Period LTM level YoY 3-year change
ACIUAC Immune S.A.LTM Mar 2026100.0% +0.0 pp+0.0 pp
PRQRProQR Therapeutics N.V.LTM Mar 202689.7% -10.3 pp-17.0 pp
SLNSilence Therapeutics plcLTM Mar 202666.4% —+23.7 pp
MREOMereo BioPharma Group plcLTM Mar 2026-105.7% ——
IMMPImmutep LimitedFY2025-1117.6% -136.1 pp-6.4 pp
CADLCandel Therapeutics, Inc.FY2025— ——
CAPRCapricor Therapeutics, Inc.FY2025— ——
CTNMContineum Therapeutics, Inc. Class A Common StockFY2025— ——
KYTXKyverna Therapeutics, Inc.FY2025— ——
LXEOLexeo Therapeutics, Inc. Common StockFY2025— ——
ALDXAldeyra Therapeutics, Inc.FY2025— ——
Peer median (excluding MREO) 78.1%-10.3 pp-3.2 pp

Competitors are the stored peer set for MREO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue49.21M010M0500K
Cost of Revenue24.17M(257.44K)2.57M1.09M133K
Gross Profit25.04M257.44K7.43M(1.09M)367K
Gross Margin50.9%—74.3%—73.4%
Research & Development31.8M30.75M17.42M20.93M17.77M
Selling, General & Admin21.5M23.18M18.42M26.43M23.01M
Operating Expenses53.3M53.92M35.84M47.36M38.62M
Depreciation & Amortization866.47K895.5K1.06M1.09M1.15M
EBITDA25.49M(39.98M)(26.06M)(40.8M)(40.47M)
EBITDA Margin51.8%—-260.6%—-8094.8%
Operating Income(28.26M)(53.67M)(28.42M)(47.36M)(38.26M)
Operating Margin-57.4%—-284.2%—-7651.4%
Interest Income1.38K696K2.13M3.04M2.17M
Interest Expense5.22M3.36M2.88M1.37M255K
Other Income / Expenses47.48M9.21M(1.58M)4.11M(3.62M)
Income Before Tax19.22M(44.46M)(30M)(43.25M)(41.88M)
Pre-Tax Margin39.1%—-300.0%—-8375.6%
Income Tax Expense2.05M(2.34M)(532K)00
Net Income17.17M(42.12M)(29.47M)(43.25M)(41.88M)
Net Margin34.9%—-294.7%—-8375.6%
EPS (Basic)749.65(1,750.35)(1,100.22)(0.29)(0.26)
EPS (Diluted)749.65(1,750.35)(1,100.22)(0.29)(0.26)
Weighted Avg Shares116.73M120.64M131.89M147.92M159.42M
Weighted Avg Shares (Diluted)116.73M120.64M131.89M147.92M159.42M

Mereo BioPharma Group plc

NASDAQ:MREO

Intrinsic Alpha fair value

Locked

Current Price

$0.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.